Authors

Mufti N. Ahmad, MD
Latest Article

Current and Emerging Immunotherapy Strategies in Advanced Urothelial Cancers

Until recently, therapeutic options for the management of advanced urothelial cancers have been limited to traditional cytotoxic agents with modest efficacy. However, the brisk pace of recent discovery in the field of immunotherapy and molecular therapeutics has ushered in a new era for management of patients with urothelial carcinoma.

Myron S.Czuczman, MD
Nadir Arber, MD, MSc, MHA
Latest Article

Prevention and Screening of CRC

Nadir Arber, MD, MSc, MHA, director of the Integrated Cancer Prevention Center (ICPC), Tel Aviv Sourasky Medical Center, discusses prevention and screening of colorectal cancer (CRC).

Naiyer Rizvi, MD
Latest Article

PD-1 and PD-L1 Antibodies in Lung Cancer

Naiyer A. Rizvi, MD, an associate attending physician, Memorial Sloan-Kettering Cancer Center, discusses PD-1 and PD-L1 antibodies in development for the treatment of lung cancer.

Nancy C. Whiting, PharmD
Nancy L. Lewis, MD
Naoto Tada Ueno, MD, PhD, FACP
Latest Article

Counting Circulating Tumor Cells

Naoto Tada Ueno, MD, PhD, FACP, from The University of Texas MD Anderson Cancer Center, discusses counting circulating tumor cells for prognostic reasons.

Narek Shaverdian, MD
Natasha Clinton, MSN, APRN, AOCNP, BCMAS
Latest Article

Differentiating Pseudoprogression From Hyperprogression in Patients Treated With Immunotherapies

Advances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.

Natisha Muhammad, MPH
Neelesh Sharma, MD, PhD
Latest Article

Novel Treatment Options for <em>T790M</em>-Mutant Non-Small Cell Lung Cancer

Despite initial clinical benefit of erlotinib and geftinib, overall efficacy of these agents is limited by emergence of drug-resistance mutations, including the gatekeeper T790M mutation.

Neelima Vidula, MD
Latest Article

Regaining Control of the Cell Cycle With CDK 4/6 Inhibitors: A Promising Targeted Therapy for Breast Cancer

Therapies targeted to tumor biology hold the promise of improved outcomes for patients with breast cancer.

Nicholas Butowski, MD
Latest Article

Convection-Enhanced Delivery of Nanoliposomal Irinotecan for Recurrent Glioblastoma or High-Grade Glioma

Nicholas Butowski, MD, discusses a phase I study of convection-enhanced delivery of nanoliposomal irinotecan (MM-398) for the treatment of recurrent glioblastoma or recurrent high-grade glioma.

Nicholas McAndrew, MD
Latest Article

Neoadjuvant Chemotherapy Considerations in Triple-Negative Breast Cancer

The optimal neoadjuvant chemotherapy regimen in triple-negative breast cancer has not been clearly defined. Achieving a pathologic complete response provides important prognostic information, and, especially in TNBC, is considered a surrogate endpoint for event-free survival.

Nicholas Nissen, MD
Nick Sambides, Jr
Latest Article

Two BRAF Fusions Discovered in Some Pan-Negative Melanomas

The discovery of two unique molecular targets known to speed skin-cancer growth has researchers excited that they might soon understand and develop genetic therapies geared toward some of medicine’s most untreatable melanomas.

Nicolas Batty, MD, FACP, FASCP
Nikita T. Patel, MD, Conor E. Steuer, MD
Latest Article

PARP-1 Inhibitors and Their Emerging Role in the Treatment of Lung Cancer

Lung cancer is one of the leading causes of death worldwide. The standard of care for advanced small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) includes platinumbased chemotherapy.

Noa Biran
Latest Article

Novel Targets in Relapsed and Relapsed/Refractory Multiple Myeloma

Current approaches to the management of multiple myeloma (MM), in particular the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), have improved the survival of patients.

Noah D. Kauff, MD, FACOG
Latest Article

Dr. Kauff Discusses Remaining Questions in the Treatment of Patients With Uterine Cancer

Noah D. Kauff, MD, FACOG, gynecologist and geneticist, director, Ovarian Cancer Screening and Prevention, Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses unanswered questions regarding the treatment of patients with uterine cancer.

Omar Al Ustwani, MD
Latest Article

Novel Therapies for <em>T315I</em>-Mutant CML

The use of tyrosine kinase inhibitors (TKIs) to inhibit BCR-ABL protein in chronic myeloid leukemia (CML) is one of the major milestones in modern oncology.

Patrice Olson
Latest Article

Biomarkers at 12 Weeks Predict Prognosis in mCRPC at 2 Years

A new biomarker panel taken 12 weeks after initiating treatment with abiraterone acetate plus prednisone can predict prognosis at 2 years in men with mCRPC, a recent analysis of the phase III COU-AA-30 pivotal trial demonstrated.

Patrick Boland, MD
Latest Article

The Role of Antiangiogenic Therapy in Previously Treated CRC

Angiogenesis is a critical factor in the propagation and metastasis of many tumor types, including colorectal cancer.

Patrick C. Ma, MD, MSc
Patrick I. Borden, MD
Latest Article

Turning the Tide on Opioid Prescribing Practices

In 2017 there was&nbsp;a continued increase in opioid-related deaths in the United States, with more than 60,000 lives lost.&nbsp;Most opioid abusers report that their opioids are acquired with their own prescription or a prescription for someone else obtained illegally.&nbsp;Two recent retrospective studies found that in patients undergoing surgery for early non&ndash;small cell lung cancer, perioperative opioid use was associated with decreased OS and increased risk of recurrence.

Patrick M. Boland, MD
Paul B. Gilman, MD
Paul Gatenby, MBBS, PhD
Paul Helft, MD
Paul Ruff, MD